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Objectives. We investigated the effect of inhaled nitric oxide and 
infused acetylcholine in patients with pulmonary hypertension 
undergoing cardiac catheterization before cardiopulmonary 
transplantation. 
Background. The fate of patients under consideration for 
transplantation of the heart or lungs, or both, is influenced by the 
evaluation of their pulmonary vascular reactivity. 
Methods. We evaluated 11 patients who were classified into two 
groups on the basis of mean left atrial pressure >15 mm Hg 
(group I, n = 6) or _<15 mm Hg (group II, n = 5). All patients 
inhaled nitric oxide at 80 ppm. This was preceded by an infusion 
of 10 -6 tool/liter of acetylcholine in seven consecutive patients 
(n = 3 in group I, n = 4 in group If). 
Results. In group I, inhaled nitric oxide decreased pulmonary 
artery pressure from (mean --- SE) 71 -+ 13 to 59 +- 10 mm Hg 
(p < 0.05), pulmonary vascular resistance from 14.9 +- 3.8 to 
7.6 --- 1.7 Um 2 (p < 0.05) and intrapulmonary shunt fraction from 
17.8 + 3.6% to 12.7 + 2.1% (p < 0.05). Left atrial pressure tended 
to increase from 27 +- 4 to 32 -+ 5 mm Hg (p = 0.07). In group II 
pulmonary vascular resistance decreased in response to nitric 
oxide from 36.4 -+ 9.0 to 31.1 +- 7.9 Um 2 (p < 0.05). Cardiac index, 
systemic pressure and resistance did not change in either group. 
Seven patients who received acetylcholine had no significant 
alteration in pulmonary hemodynamic variables. 
Conclusions. These preliminary observations uggest that nitric 
oxide is a potent pulmonary vasodilator with minimal systemic 
effects. It may be useful in discriminating patients needing 
combined heart and lung transplantation from those requiring 
exchange of the heart alone. 
(J Am CoU Cardiol 1995;25:1656-64) 
The fate of patients under consideration for transplantation f 
the heart or lungs, or both, is influenced by the evaluation of 
their pulmonary vascular eactivity. Successful reduction of an 
elevated pulmonary vascular resistance may delay the need for 
transplantation r permit exchange of the heart alone (1-3). 
Pulmonary hypertension was established as an adverse prog- 
nostic factor for cardiac transplantation in early reports (4) and 
remains a significant risk factor for early death despite contin- 
ued improvement in survival of high risk patients (5,6). Cur- 
rent pulmonary vascular assessment often relies on intrave- 
nously infused vasodilators. Their administration is not without 
hazard, and the hemodynamic results may be confounded by 
changes in cardiac output, systemic hypotension and hypox- 
emia secondary to increased intrapulmonary shunting (7). In 
contrast, the inhalation of nitric oxide has been shown to 
vasodilate the human pulmonary vascular bed with minimal 
systemic effects and without increasing intrapulmonary shunt- 
ing (8-14). The systemic effects of inhaled nitric oxide are 
limited by its avid affinity for, and subsequent inactivation by, 
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hemoglobin (15). Evidence is accumulating that the production 
of nitric oxide from L-arginine by the endothelial cell mediates 
vessel tone through a cyclic guanosine monophosphate 
(cGMP)-dependent mechanism in both the systemic and pul- 
monary circulations (16-19). 
The vascular esponse to acetylcholine, an endothelium- 
dependent vasodilator (20), is regarded as a measure of 
endothelial cell integrity and has been documented to be 
abnormal in a number of vascular diseases (21,22). The 
pulmonary vascular esponse to acetylcholine may be abnor- 
mal after cardiopulmonary bypass (9) and in patients with 
congestive heart failure and secondary pulmonary hyperten- 
sion (23). If decreased production of endogenous nitric oxide is 
responsible for vasoconstriction i  patients with pulmonary 
hypertension rather than obliteration of the pulmonary vascu- 
lature, then administration of nitric oxide might achieve pul- 
monary vasodilation. Therefore, we investigated the effects of 
nitric oxide inhalation and acetylcholine infusion on the hemo- 
dynamic variables and gas exchange inpatients with pulmonary 
hypertension undergoing cardiac catheterization as part of 
their assessment before consideration for cardiopulmonary 
transplantation. 
Methods  
Patients. We evaluated 11 patients (median age 13 years, 
range 0.7 to 27) with pulmonary hypertension (mean [_SE] 
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Table 1. Pretransplantation Diagnoses of Patients 
Age 
Pt No./Gender (yr) Diagnosis 
1/M 2 Shone syndrome variant 
2/F 8 Shone syndrome variant 
3/F 9 Idiopathic restrictive cardiomyopathy 
4/F 13 Ventricular failure after Senning 
procedure for TGA and VSD 
Adriamycin-induced cardiotoxicity 
Shone syndrome variant; severe MR 
Primary pulmonary hypertension 
(right to left atrial shunt) 
Cystic fibrosis 
Eisenmenger complex with small 
VSD 
Eisenmenger complex with ASD 
Eisenmenger complex with VSD and 
pulmonary artery band 
5/M 20 
6/F 26 
7/M 0.7 
8/F 11 
9/17 14 
10/F 23 
11/M 27 
ASD (VSD) = atrial (ventricular) septal defect; F = female; M = male; MR 
= mitral regurgitation; Pt = patient; TGA = transposition f the great arteries. 
pulmonary artery pressure 71.6 + 8.4 mm Hg) who underwent 
cardiac catheterization to assess their pulmonary vascular 
resistance and reactivity as part of their pretransplant manage- 
ment (Table 1). The patients were classified into two groups on 
the basis of a mean left atrial pressure >15 mm Hg (group I) 
or -<15 mm Hg (group II) and coinciding with whether they 
were combined heart and lung or lung transplant candidates, 
respectively. Thus, group I had an elevated mean left atrial 
pressure (27.0 _+ 4.2 mm Hg) and treatment options potentially 
restricted to combined heart and lung transplantation. In
contrast, group II had a low mean atrial pressure (7.2 + 
1.3 mm Hg), and these patients were considered candidates for 
lung transplantation. The difference in left atrial pressure was 
significant (p < 0.05). The only other difference in the mea- 
sured baseline variables between the groups was a higher ight 
atrial pressure in group I. There was a tendency for group I to 
have a higher partial pressure of arterial oxygen (Pao2) (p = 
0.05) and lower pulmonary vascular esistance (Table 2). 
Group I: high left atrial pressure. Group I included six 
patients (Patients 1 to 6) with an elevated pulmonary vascular 
resistance (mean 14.9 + 3.8 Um 2) and transpulmonary gradi- 
ent (mean 44.7 _+ 12.2 mm Hg) in the setting of severe left 
ventricular failure despite optimal medical management with 
digoxin, diuretic drugs and, when appropriate, maximal after- 
load reduction therapy. 
Patients 1, 2, and 6 were diagnosed as having Shone 
syndrome variants. Patients 1 and 2 had an elevated end- 
diastolic pressure, mild mitral stenosis (previous mitral valve 
replacement in Patient 1) and moderate left ventricular out- 
flow tract obstruction. Patient 6 had undergone mitral valve 
replacement (twice) and aortic valve replacement. In addition, 
a ventricular septal defect and aortic coarctation were repaired 
in infancy. Her predominant lesion was severe perivalvar 
mitral regurgitation not amenable to surgical correction. Two 
other patients had acquired cardiomyopathies (idiopathic in 
Patient 3 and secondary to adriamycin treatment for leukemia 
12 years earlier in Patient 5). Patient 4 had right ventricular 
(systemic ventricular) failure after a Senning procedure with 
ventricular septal defect closure for transposition of the great 
arteries in infancy. Subsequently, she had undergone tricuspid 
valve (systemic atrioventricular valve) replacement. 
Group II: low left atrial pressure. Group II included five 
patients (Patients 7 to 11) who had pulmonary hypertension 
with an elevated pulmonary vascular esistance (mean 36.4 +_ 
9.0 Um z) but with preserved ventricular function. Two patients 
had primary lung pathology (Patient 7 had primary pulmonary 
hypertension; Patient 8 had cystic fibrosis). Three patients had 
pulmonary hypertension associated with congenital intracar- 
diac shunts and had developed the Eisenmenger complex. 
Patient 9 had a large ventricular septal defect in infancy but 
had developed progressive levation of pulmonary vascular 
resistance despite spontaneous reduction in the size of the 
defect. Patient 10 had an atrial septal defect with reversed 
shunting, and Patient 11 had a large ventricular septal defect 
and developed pulmonary vascular disease after an inadequate 
pulmonary artery band placed in infancy. These three patients 
were considered for lung transplantation with primary cardiac 
repair (24). 
Hemodynamie assessment. Seven consecutive patients 
were investigated with both acetylcholine and nitric oxide 
(Patients 1, 3, 4, 7, 8, 10 and 11), and four patients received 
nitric oxide gas alone (Patients 2, 5, 6 and 9) because we had 
discontinued the use of acetylcholine as a pulmonary vasodi- 
lator at the time of their assessment. During cardiac atheter- 
ization but before angiography, hemodynamic measurements 
were recorded at baseline, during a 2-rain infusion of acetyl- 
choline, 15 rain after return to a steady baseline and after 
15 rain of nitric oxide inhalation (80 ppm). In two patients we 
recorded hemodynamic variables at 40 as well as 80 ppm. In 
addition to receiving nitric oxide preoperatively, Patient 4 was 
studied after heart transplantation. 
The hemodynamic variables recorded were heart rate, 
systemic and pulmonary arterial pressures, right and left atrial 
pressures, arterial and venous blood gases and oxygen satura- 
tion. In six patients (Patients 1 to 3, 5, 6 and 8) without 
tricuspid or pulmonary regurgitation or intracardiac shunting, 
cardiac output was measured by thermodilution, and left atrial 
pressure from pulmonary artery wedge pressures. In four 
patients with intracardiac shunts (Patients 7 and 9 to 11) and 
one with pulmonary regurgitation (Patient 4), the systemic and 
pulmonary blood flows were estimated using the Fick principle. 
Oxygen consumption was measured (Waters Inc., model 
MM20). Oxygen saturation was measured by co-oximetry in 
blood drawn from systemic artery, pulmonary artery, systemic 
vein and pulmonary vein or left atrium. All preoperative 
studies were conducted with the patients awake and breathing 
spontaneously but sedated with midazolam and morphine. The 
postoperative study in Patient 4 was conducted uring mechan- 
ical ventilation. 
Delivery and monitoring of nitric oxide. The details of 
nitric oxide gas preparation, delivery and monitoring have 
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Table 2. Hemodynamic Response to Inhaled Nitric Oxide 
Group I: Patients With High Left Atrial Pressure 
CI 
BP PAp (liters/min PAWp/LAp RAp SVRI PVRI HR Pao 2 TPG Qs/Qt 
Pt No. (ram Hg) (mm Hg) per m 2) (mm Hg) (ram Hg) (Urn 2) (Um 2) (beats/min) (ram Hg) (mm Hg) (%) 
5 
6 
Mean _+. SE 
1 Baseline 69 92 3.4 16 
NO 80 ppm 72 84 4.7 26 
2 Baseline 80 120 2.9 32 
NO 80 ppm 100 90 3.4 45 
3 Baseline 74 56 3.1 26 
NO 80 ppm 66 40 3.1 26 
4 Baseline 67 45 2,6 22 
NO 40 ppm 70 37 2.4 22 
NO 80 ppm 67 35 2.4 22 
Baseline 75 37 2.0 21 
NO 80 ppm 75 34 2.1 24 
Baseline 65 80 3.4 45 
NO 80 ppm 70 70 4.0 50 
Baseline 72 -+ 2 72 _+ 13 2.9 _+ 0.2 27 _+ 
NO 80ppm 75+-5 59_+I0 3.3+-0.4 32_+ 
10 17.4 22.4 148 65 76 26.8 
10 13.2 12.3 148 76 58 19.7 
18 21.4 30.3 130 53 88 25.6 
18 24.1 13.2 100 84 45 17.5 
10 20.6 9.7 85 96 30 10.7 
10 18.1 4.5 80 89 14 8.2 
8 22.7 8.8 61 90 23 13.5 
5 27.1 6.3 73 NA 15 NA 
5 25.8 5.4 73 96 13 12.2 
14 30.5 8.0 75 102 16 6.2 
14 29.0 4.8 70 100 10 6.1 
40 7.4 10.3 83 107 35 23.8 
40 7.5 5.0 111 327 20 12.7 
17 -+ 5 20.0 -+ 3.1 14.9 +- 3.8 97 + 14 86 -+ 9 45 -+ 12 17.8 -+ 3.6 
16 + 5 19.6 -+ 8.2 7.6 -+ 1.7 97 -+ 12 129 + 40 27 -+ 8 12.7 -+ 2.1 
Group II: Patients With Low Left Atrial Pressure 
CI PBFI 
BP PAp (liters/min (liters/min PAWp/LAp RAp SVRI PVRI HR Pao 2 TPG 
Pt No. (ram Hg) (mm Hg) per m e) per m z) (mm Hg) (mm Hg) (Urn 2) (Urn 2) (beats/rain) (mm Hg) (mm Hg) 
7 Baseline 56 80 2.7 1.9 7 6 18.5 38.4 152 46 73 
NO 80 ppm 57 82 3.0 2.1 7 6 17.0 35.7 153 48 75 
8 Baseline 100 30 3.5 3.5 12 7 26.6 5.1 80 NA 18 
NO 80 ppm 95 27 3.5 3.5 13 7 25.1 4.0 80 NA 14 
9 Baseline 75 80 2.3 1.6 6 6 30.0 46.3 79 58 74 
NO 40 ppm 75 80 2.1 1.7 7 6 32.9 42.9 80 NA 73 
NO 80 ppm 75 74 2.3 1.8 6 6 30.0 37.8 83 62 68 
10 Baseline 116 66 2.4 1.9 4 4 46.7 32.6 142 57.0 62 
NO 80 ppm 116 66 3.2 2.3 6 5 34.7 26.1 156 57.0 60 
11 Baseline 107 102 2.7 1.6 7 7 37.0 59.4 75 41 95 
NO 80 ppm 105 100 2.9 1.8 7 7 33.8 51.7 75 42 93 
Mean _+ SE Baseline 91 -+ 11 72 _+ 12 2.7 _+ 0.2 2.1 _+ 0.4 7 -+ 2 6 _+ 1 31.8 _+ 4.8 36.4 --- 9.0 106 _+ 17 51 _+ 4 64 _+ 13 
NO 80ppm 90-+11 70-+12 3.0+-0.2 2.3+0.3 8_+1 6_+1 28.1_+3.3 31.1 +7.9 109_+18 52_+4 62+13 
Baseline = before nitric oxide (NO); BP = mean systemic arterial pressure; CI = cardiac index; HR = heart rate; LAp = left atrial pressure; NA = not available; 
Pao 2 = systemic arterial oxygen tension; PAp = mean pulmonary artery pressure; PAWp = pulmonary artery wedge pressure; PBFI = pulmonary blood flow index; 
Pt = patient; PVRI = pulmonary vascular resistance index; QdQt = intrapulmonary shunt fraction; RAp = fight atrial pressure; SVRI = systemic vascular resistance 
index; TPG = transpulmonary gradient. 
been reported elsewhere (9,25). In brief, nitric oxide gas (Scott 
Specialty Gases) of medical grade quality and conforming to 
Food and Drug Administration guidelines was supplied in 
tanks in a concentration f 800 ppm. Pure nitrogen and nitric 
oxide were fed separately into a Bird (Bird Products Corpora- 
tion) low flow blender at 50 psi. This blender controlled the 
proportion of nitric oxide and nitrogen mixture that flowed 
into a second Bird blender, where it was blended with oxygen. 
The fraction of inspired oxygen delivered to the patient could 
thus be adjusted (between 0.21 and 0.97) independently of the 
nitric oxide. The gas flow distal to the oxygen blender was 
controlled by a standard oxygen flowmeter. This gas mixture 
was delivered to the patient hrough a one-way inspiratory 
valve to a face mask. An in-line oxygen analyzer was positioned 
between the flowmeter and the face mask. The mask was hand 
held by an investigator to fit snugly over the patient's face. The 
expiratory gases from the patient circuit were scavenged by a 
reservoir bag and regulated wall suction. Nitric oxide and 
nitrogen dioxide levels were monitored by chemiluminescence. 
A sampling port at the airway permitted a volume of inspira- 
tory gas mixture to flow to the analyzer (Thermoenvironmental 
Instruments Chemiluminescence, model 42H). 
Methemoglobin levels were measured after nitric oxide 
inhalation with a co-oximeter (CIBA-Corning, model 2500) 
using a multiwavelength spectrophotometric method. 
Acetylcholine. Acetylcholine was diluted in 5% dextrose to 
yield a concentration of 10 .6 mol/ml and infused into the 
pulmonary artery at a rate (in ml/min) equal to the baseline 
pulmonary blood flow (in liters/rain), to achieve a final con- 
centration in the pulmonary circulation of 10 6 mol/liter for all 
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Table 3. Hemodynamic Response to 10 6 mol/liter of Acetylcholine Infused Over 2 min 
Group I: Patients With High Left Atrial Pressure 
CI 
BP PAp (liters/mfu PAWp/LAp RAp SVRI PVRI HR Pao 2 TPG QJQt 
Pt No. (mm Hg) (mm Hg) per m 2) (mm Hg) (mm Hg) (Um 2) (Urn 2) (beats/min) (mm Hg) (mm Hg) (%) 
1 Baseline 65 91 4.0 15 10 13.8 19.0 146 65 76 NA 
ACh 60 91 4.3 15 10 11.6 17.7 146 67 76 NA 
3 Baseline 62 52 3.1 19 10 16.8 10.6 85 92 33 11.0 
ACh 66 52 3.0 18 10 18.7 11.3 90 83 34 18.0 
4 Baseline 58 36 2.2 . 16 7 23.2 9.1 61 94 20 11.7 
ACh 55 33 2.2 16 6 22.3 7.7 60 90 17 11.8 
Mean _+ SE Baseline 62 _+ 2 60 _+ 16 3.1 _+ 0.5 17 _+ 1 9 -+ 9 17.9 +_ 2.8 12.9 _+ 3.1 97 _+ 25 84 _+ 9 43 + 17 11.4 _+ 0.4 
ACh 60 _+ 3 59 -+ 17 3.2 _+ 0.6 16 + 1 9 +_ 1 17.5 + 3.1 12.2 _+ 2.9 99 -+ 25 80 _+ 7 42 _+ 18 14.9 _+ 3.1 
Group II: Patients With Low Left Atrial Pressure 
CI PBFI 
BP PAp (titers/min (liters/min PAWp/LAp RAp SVRI PVRI HR Pao 2 TPG 
Pt No. (mm Hg) (mm Hg) per m 2) per m 2) (mm Hg) (ram Hg) (Urn 2) (Um 2) (beats/min) (mm Hg) (ram Hg) 
7 Baseline 58 86 2.3 1.4 6 6 22.6 57.1 165 42 80 
ACh 58 88 2.8 1.5 6 6 18.4 54.7 165 41 82 
8 Baseline 104 31 4.2 4.2 13 7 23.1 4.3 101 NA 18 
ACh 103 27 4.0 4.0 12 7 24.0 3.8 90 NA 15 
10 Baseline 118 70 3.2 2.1 6 4 35.6 30.5 146 60 64 
ACh 116 66 2.9 2.1 7 4 38.6 28.1 146 61 59 
11 Baseline 105 101 2.7 2.3 7 8 35.9 40.9 75 43 94 
ACh 105 101 2.6 2.2 7 7 37.7 42.7 75 43 94 
Mean _+ SE Baseline 96 + 13 72 _+ 15 3.1 _+ 0.4 2.5 _+ 0.6 8 -+ 2 6 _+ 1 28.7 _+ 4.1 33.2 _+ 11.1 122 _+ 21 48 _+ 5 64 _+ 17 
ACh 96 _+ 13 71 _+ 16 3.1 _+ 0.4 2.5 _+ 0.5 8 _+ 1 6 +_ 1 29.2 _+ 5.4 32.3 _+ 11.0 119 + 22 48 _+ 6 63 + 17 
ACh = after acetylcholine infusion; Baseline = before acetylcholine; BP = mean systemic arterial pressure; CI - cardiac index; HR = heart rate; LAp = left atrial 
pressure; NA = not available; Pa% - systemic arterial oxygen tension; PAp = mean pulmonary artery pressure; PAWp - pulmonary artery wedge pressure; 
PBFI = pulmonary blood flow index; Pt = patient; PVRI = pulmonary vascular resistance index; Qs/Qt = intrapulmonary shunt fraction; RAp right atrial pressure; 
SVRI = systemic vascular resistance index; TPG = transpulmonary gradient. 
patients, independent of differences in pulmonary blood flow. 
In earlier studies this dose of acetylcholine had reliably caused 
pulmonary vasodilation with minimal systemic effects in chil- 
dren with congenital heart disease undergoing preoperative 
cardiac atheterization (9). 
Statistical analysis and calculations. The change in the 
hemodynamic variables between baseline and in response to 
acetylcholine and nitric oxide was compared with a nonpara- 
metric test for repeated measures (Friedman), and when 
differences were found, a Wilcoxon signed-rank test was used. 
A p value <0.05 was considered significant. The differences 
between groups I and II were analyzed using a Mann-Whitney 
U Test. 
Standard equations were used to calculate systemic and 
pulmonary vascular esistances and were indexed to body 
surface area. To calculate the intrapulmonary shunt fraction 
(Qs/Qt) in patients with high left atrial pressure, we applied the 
equation as described by Riley and Cournand (26). 
Ethical approval and informed consent. The investigation 
was approved by the Children's Hospital Investigational Re- 
view Board and reported to the Food and Drug Administra- 
tion. Written informed consent was obtained from the patients 
or their parents. 
Resu l ts  
Individual patient responses to inhaled nitric oxide and 
aeetylcholine are displayed in Tables 2 and 3, respectively. 
Effect of nitric oxide. Nitric oxide in group I (patients with an 
elevated left atrial pressure). Group I patients displayed marked 
pulmonary vascular reactivity in response to nitric oxide. 
Pulmonary artery pressure decreased from 71.7 _+ 12.9 to 
58.8 _+ 10.4 mm Hg (p < 0.05); pulmonary vascular resistance 
decreased from 14.9 +_ 3.8 to 7.6 _+ 1.7 Um 2 (p < 0.05); and 
transpulmonary gradient was reduced from 44.7 _+ 12.2 to 
26.7 _+ 8.1 mm Hg (p < 0.05) (Table 2). The intrapulmonary 
shunt fraction decreased from 17.8 _+ 3.6% to 12.7 _+ 2.1% 
(p < 0.05). There was a tendency for left atrial pressure to 
increase (27.0 _+ 4.2 to 32.2 _+ 4.9 mm Hg, p = 0.07). Cardiac 
index was 2.9 _+ 0.2 liters/rain per m 2 at baseline and 3.3 _+ 0.4 
liters/rain per m 2 with nitric oxide. Systemic vascular resistance 
index and blood pressure did not change with nitric oxide. All 
six patients had a baseline pulmonary vascular esistance ->8 
Um 2, thereby potentially eliminating transplantation f the 
heart alone. However, four patients responded to inhaled 
nitric oxide with a reduction in pulmonary artery pressure that 
reduced pulmonary vascular resistance <6.0 Um 2 and in three 
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patients transpulmonary gradient <15 mm Hg such that their 
transplantation status was altered from combined heart and 
lung transplantation to heart transplantation alone. Two of 
these patients (Patients 3 and 4) underwent successful cardiac 
transplantation with a low pulmonary vascular resistance in the 
postoperative p riod. Three days after cardiac transplantation, 
Patient 4 had a pulmonary artery pressure of 41 mm Hg and 
pulmonary vascular esistance of 5.5 Um 2, identical to that 
predicted by the preoperative assessment with nitric oxide. 
There was a further eduction in pulmonary artery pressure to 
36 mm Hg and in pulmonary vascular resistance to 4.2 Um 2 in 
response to inhaling nitric oxide for 15 min. 
Patient 3 had a mean pulmonary artery pressure in the 
immediate postoperative p riod of 25 mm Hg, with a pulmo- 
nary vascular esistance of 3.5 Um 2. One month after trans- 
plantation, mean pulmonary artery pressure was 26 mm Hg 
and pulmonary vascular esistance 6.2 Um 2. Patient 3 died 2 
months after cardiac transplantation and after hospital dis- 
charge of acute graft rejection. 
There were three additional deaths. Patient 1 died after 
heart and lung transplantation, Patient 2 during an intercur- 
rent pneumonia while awaiting a heart and lung donation and 
Patient 6 while awaiting a donor heart. Patient 5 is awaiting 
cardiac transplantation. 
Important increases in left atrial pressure and cardiac index 
were confined to Patients 1, 2, and 6, who carried the diagnosis 
of Shone syndrome variants. All three patients had a suprasys- 
temic pulmonary artery pressure but no intracardiac shunt. 
In patients 1 and 2, left atrial pressure returned toward 
baseline at 18 and 33 mm Hg, respectively, 15 min after 
discontinuing the inhalation of nitric oxide. 
Nitric oxide in group II (patients with a low left atrial 
pressure). Although there was a statistically significant de- 
crease in pulmonary vascular esistance from 36.4 + 9.0 to 
31.1 + 7.9 Um 2 (p < 0.05), the changes in pulmonary 
hemodynamic variables were not clinically important (Table 
2). There was a tendency for pulmonary artery pressure to 
decrease and for pulmonary blood flow to increase. Only 
Patient 8 with cystic fibrosis responded to nitric oxide with a 
10% decline in pulmonary artery pressure and a 21% decline 
in pulmonary vascular esistance. Patient 8 underwent lung 
transplantation, and the four other group II patients are 
awaiting transplantation. 
Effect of aeetyleholine. In the seven patients who received 
acetylcholine, there was no overall significant alteration in 
pulmonary hemodynamic variables. The decrease in pulmo- 
nary vascular esistance was significantly less than that with 
nitric oxide (p < 0.05) (Table 3). 
Acetylcholine in group I (patients with a high left atrial 
pressure). Three of six patients received acetylcholine. No 
patient responded with a larger decrease in pulmonary artery 
pressure or pulmonary vascular resistance than that with nitric 
oxide. Acetylcholine did not change pulmonary artery pressure 
in two patients (Patients 1 and 3), but pulmonary vascular 
resistance increased by 6.5% in Patient 3 and decreased by 7% 
in Patient 1, associated with changes in cardiac index. Patient 
4 responded with an 8% decrease inpulmonary artery pressure 
and a 15% decrease in pulmonary vascular esistance without 
a change in cardiac index. 
Acetylcholine in group II (patients with a low left atrial 
pressure). Four of five patients received acetylcholine. Patient 
8 with cystic fibrosis responded with a 13% decrease in 
pulmonary artery pressure and a 12% decrease in pulmonary 
vascular resistance. Patient 11 responded with a small increase 
in pulmonary vascular esistance (4.5%) accompanied by a 
small decrease in pulmonary blood flow (4.5%). 
Differences between groups I and II. The difference in the 
responses of patients with a high versus low left atrial pressure 
is evident from Table 2. The percent change in pulmonary 
artery pressure (p < 0.05), pulmonary vascular resistance (p < 
0.01) and transpulmonary gradient (p < 0.01) were signifi- 
cantly greater with nitric oxide in group I than group II. 
Pathologic findings. Pathologic examination of the heart in 
three of the patients who died (Patients 1, 2, and 6) confirmed 
the clinical diagnosis and demonstrated very hypertrophied left 
atrial and ventricular walls with extensive ndocardial fibro- 
elastosis. Vascular histologic examination of the lungs in 
Patients 1 and 2 demonstrated changes of grades 3 to 4 and 
grade 2 in Patient 6 according to the classification of Heath and 
Edwards (27). Left ventricular cavity size was reduced in 
Patients 1 and 2. 
Nitrogen dioxide and methemoglobin. Nitrogen dioxide 
levels remained <1 ppm throughout exposure to nitric oxide in 
all patients. Methemoglobin levels ranged from 0% to 0.9% 
(mean 0.4 +_ 0.1%, normal reference range 0% to 5%). 
Discuss ion 
General findings. This preliminary evaluation suggests that 
nitric oxide was effective in lowering pulmonary artery pressure 
and pulmonary vascular esistance without important systemic 
effects in a small group of patients undergoing assessment of
pulmonary vascular reactivity as a prelude to cardiopulmonary 
transplantation. The response was most clinically important in 
the group of patients with ventricular failure and left atrial 
hypertension. On the basis of the response to nitric oxide, four 
patients were reclassified to receive heart transplantation 
alone, and two did so with low pulmonary vascular resistance in
the postoperative period. In the two patients in whom the 
challenge with inhaled nitric oxide failed to lower pulmonary 
vascular esistance adequately, histologic examination of the 
explanted lungs confirmed severe pulmonary vascular disease. 
We suggest that nitric oxide may be useful in further discrim- 
inating between those patients needing combined cardiopul- 
monary transplantation a d those for whom cardiac replace- 
ment alone is sufficient. In contrast to assessment of pulmonary 
vascular reactivity with intravenous vasodilators, use of inhaled 
nitric oxide minimizes confounding variables, such as systemic 
vasodilation and concomitant changes in cardiac output, and 
simplifies the interpretation of changes in pulmonary vascular 
resistance (11,28,29). However, because we did not compare 
endothelium-independent intravenous vasodilators, such as 
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prostacyclin or sodium nitroprusside, with inhaled nitric oxide, 
we cannot exclude the possibility that the response to these 
agents would have been similar in our patients. 
Although 7 of the 11 patients in the present study had 
congenital heart disease with pulmonary hypertension, they 
differ from patients reported previously because of the ad- 
vanced nature of their pulmonary hypertension (8,9). 
Nitric oxide and heart versus heart and lung transplanta- 
tion. Elevated pulmonary vascular esistance is regarded as a 
risk factor before cardiac transplantation (1,30), manifested 
primarily by an increased risk of postoperative right ventricular 
failure (4-6,31). Patients with pulmonary and left atrial hyper- 
tension often have a reversible component totheir pulmonary 
hypertension if the underlying cause can be relieved (32). 
Therefore, assessment ofthe reversibility and quantification f 
• the pulmonary vascular disease are important before trans- 
plantation. Limited numbers of donor organs further dictate 
that accurate assessment of the lowest achievable pulmonary 
vascular esistance be made, thereby limiting combined heart 
and lung transplantations and ensuring more effective distri- 
bution and proper use of scarce resources. 
Patients with left atrial hypertension may have a high 
calculated pulmonary vascular esistance because the cardiac 
index is low, the pulmonary vasculature is constricted, or there 
is fixed pulmonary vascular obstructive disease with a reduc- 
tion in recruitable lung vessels. Preoperative assessment may 
be aimed at increasing cardiac output with drugs such as 
dobutamine or combining vasodilation and an increase in 
cardiac output with drugs such as nitroprusside or prostacydin. 
The use of catecholamines or systemic vasodilators is not 
without risk, especially in patients with left ventricular outflow 
tract obstruction, as in two of our patients, or in patients with 
increased susceptibility oarrhythmias. The use of vasodilators 
is often limited because of systemic hypotension ran increase 
in intrapulmonary shunt resulting in hypoxemia, which further 
confounds assessment ofpulmonary vasoconstriction (2,3,28). 
Nitric oxide produced a decrease inpulmonary artery pressure 
and pulmonary vascular esistance and a decrease in intrapul- 
monary shunt fraction without important changes in heart rate, 
systemic vascular resistance, systemic blood pressure or cardiac 
output. This is concordant with findings in other elated studies 
(9 -14,29). 
The effect of nitric oxide in the three patients with the 
diagnosis of Shone syndrome variant was interesting. Both 
patients had suprasystemic right ventricular pressure and 
responded to nitric oxide not only with marked reduction in 
pulmonary artery pressure and resistance, but also with a 
substantial increase in cardiac output associated with an ele- 
vation in left atrial pressure. One might postulate that when 
right ventricular pressure issuprasystemic, reductions inafter- 
load result in an increase in cardiac output because of reduced 
left ventricular deformation and improved right ventricular 
perfusion and performance. The increased cardiac output may 
then cause an increase in left atrial pressure if there is either 
mitral stenosis or a noncompliant left atrium and ventricle. 
Indeed, Wood et al. (33) made the insightful observation that 
in patients with mitral stenosis, ymptoms of pulmonary edema 
were rare among those with the highest pulmonary vascular 
resistances, which led them to show that lowering pulmonary 
vascular resistance in such patients could lead to an increase in 
left atrial pressure and cardiac output. This was most marked 
in our patients with end-stage Shone disease and congenitally 
small, noncompliant left atria and ventricles. Kieler-Jensen et 
al. (28) reported an increase in pulmonary artery wedge 
pressure after inhalation of nitric oxide in adult patients with 
acquired cardiomyopathies. We did not witness uch an eleva- 
tion in left atrial pressure after a trial of nitric oxide in other 
patients (25). The hemodynamic effects of nitric oxide are 
quickly reversed when it is withdrawn (8,11,14,28,34), thus 
limiting any lasting adverse sequelae. Nevertheless, precipita- 
tion of pulmonary edema was reported after a trial of nitric 
oxide (35) and highlights the need for careful observation and 
intensive monitoring during its administration. 
In Patient 4, nitric oxide further reduced postoperative 
pulmonary artery pressure and pulmonary vascular esistance. 
Nitric oxide has been used with success in the postoperative 
cardiac patient (9,10) and after cardiac transplantation to 
support a patient with transient right ventricular failure (36). 
Patients with pulmonary hypertension and transient graft 
dysfunction after lung transplantation have benefited from 
prolonged treatment with nitric oxide (14). Nitric oxide may 
prove to be a useful addition to the pharmacologic support of 
patients with elevated pulmonary vascular resistance and poor 
right ventricular function after heart ransplantation. 
Clinical effects of nitric oxide. The striking response of the 
pulmonary circulation to nitric oxide in patients with pulmo- 
nary venous hypertension is evident from other published 
reports (10). There is evidence that endogenous nitric oxide 
mediates vasodilation ofpulmonary veins, perhaps to a greater 
extent han arteries in the lamb lung (37). We speculate that 
the particular efficacy of inhaled nitric oxide in patients with 
left atrial hypertension may be related to the sensitMty of 
pulmonary veins to nitrovasoditation. 
In the patients with a high left atrial pressure there was a 
small increase in Pao 2 in response to nitric oxide from 86 to 
129 mm Hg and a significant decrease in intrapulmonary shunt 
fraction. Other studies (9,10) reported no change in Pao 2 in 
patients with pulmonary hypertension but without air space 
disease treated with nitric oxide either before or after cardiac 
surgery. In contrast, he use of intravenous vasodilators may be 
associated with an increase in intrapulmonary shunt fraction 
with a decrease in Pao2 unless cardiac output increases (38). 
We found that in both patients who received two doses of 
nitric oxide, 80 ppm resulted in a greater decrease in pulmo- 
nary artery pressure than a dose of 40 ppm. Pepke-Zaba et al. 
(11) used a nitric oxide dose of 40 ppm to alter pulmonary 
hemodynamic variables in patients with primary pulmonary 
hypertension. Both animal and human studies suggest addi- 
tional responses with doses of 80 versus 40 ppm (8,39). When 
nitric oxide is used to treat ventilation-perfusion ab ormali- 
ties, a lower dose may be more effective and more appropriate 
because therapy is usually prolonged (29,40,41). However, 80 
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ppm may be justified for a short trial and when the aim is the 
lowest possible pulmonary artery pressure and resistance, and 
the risk of toxicity is minimal. Nitric oxide may form more 
stable dinitrosyl-Fe 2+ complexes and S-nitrosylated proteins 
(42). Nitric oxide, thus bound, could be released at a distant 
site and cause vasodilation. It is thus possible that systemic 
effects are marginally greater in some patients with a dose of 
80 ppm, as we observed in Patient 3. 
Comparative response to nitric oxide in patients with a low 
left atrial pressure. There was minimal response to inhaled 
nitric oxide in the patients with primary pulmonary hyperten- 
sion and the Eisenmenger complex (group II) in whom intimal 
proliferation obliterates small pulmonary vessels and reduces 
pulmonary vascular cross-sectional area. The pulmonary arte- 
riopathy of pulmonary venous hypertension may be character- 
ized by muscular hypertrophy as well as intimal proliferation. 
However, intimal proliferation develops very slowly and does 
not become occlusive, resembling inmany ways the pulmonary 
vascular changes of normal aging in contrast o the vessel 
histologic appearance in pulmonary vascular obstructive dis- 
ease (43,44). The poor response to nitric oxide in the patients 
with advanced pulmonary vascular disease was not surprising. 
Indeed, the response to vasodilator therapy has been shown to 
be reduced in patients with an increased intimal area on lung 
biopsy (45). 
The prognosis for patients with primary pulmonary hyper- 
tension is poor. However, some patients may have a favorable 
response to an infused vasodilator, and their outcome may 
improve with long-term administration of calcium channel 
blockers or prostacyclin (46,47). The use of systemic vasodila- 
tor therapy may be hazardous in these patients (7). Therefore, 
most would recommend a trial of a short-acting vasodilator, 
such as prostacyclin, to elicit reactivity (38). The effects of 
prostacyclin and inhaled nitric oxide have been compared in 
primary pulmonary hypertension (which, when advanced, is 
histologically indistinguishable from the pulmonary vascular 
changes of the Eisenmenger complex). Pepke-Zaba et al. (11) 
found a comparable change in pulmonary hemodynamic vari- 
ables with both agents but considered nitric oxide to be more 
specific and selective. It has been suggested (47) that the 
improved survival in some patients on long-term prostacyclin 
therapy is unrelated to its short-term effects and may be related 
either to antiproliferative effects on smooth muscle or antiag- 
gregatory effects on platelets. Nitric oxide is present in the 
exhaled breath of humans (48) and may also have antiprolif- 
erative effects on smooth muscle and inhibit platelet adhesion 
(49,50). It is possible that in suitable patients low dose inhala- 
tion of nitric oxide might be useful in the treatment of chronic 
pulmonary hypertension both by reversing the vasoconstrictor 
component when present and retarding or reversing the oblit- 
eration of the pulmonary vascular bed. However, potential 
long-term toxicity must be considered seriously. 
Effect of acetylcholine. In the seven consecutive patients 
tested with both acetylcholine and nitric oxide, the decline in 
pulmonary vascular esistance with nitric oxide was greater. 
Indeed, in two patients, one with high left atrial pressure and 
one with low left atrial pressure, there was a small increase in 
pulmonary vascular resistance with acetylcholine. Only Patient 
7 with cystic fibrosis responded with a similar decrease in 
pulmonary vascular esistance to both agents. 
The decreased response to acetylcholine with preservation 
of the response to nitric oxide suggests that endothelium- 
dependent relaxation may be impaired but that the smooth 
muscle still retains the capacity to relax. Even though present 
initially, pulmonary vascular dilation in response to acetylcho- 
line may be lost with the progression of primary pulmonary 
hypertension (51), and although this may be due to an increase 
in vessel occlusion, our results suggest hat testing with an 
endothelium-independent vasodilator would seem prudent. 
There is evidence that the endothelium is dysfunctional in
patients with pulmonary hypertension, which may contribute to 
the vascular changes een histologically (52). Explanted pre- 
constricted pulmonary artery rings in patients with cystic 
fibrosis and the Eisenmenger complex demonstrate impair- 
ment of endothelium-dependent r laxation (53). In vivo, the 
biosynthesis ofprostacyclin (an endothetium-derived asodila- 
tor) is reduced compared with that of thromboxane in patients 
with the Eisenmenger complex (54). In the present study there 
was an increase in pulmonary vascular resistance with a 
decrease inpulmonary blood flow in one patient with advanced 
pulmonary vascular disease and a ventricular septal defect. 
Paradoxic onstriction was reported in explanted pulmonary 
artery rings from patients with the Eisenmenger complex at an 
identical dose of 10 -6 tool/liter of acetylcholine (53). However, 
the patient with cystic fibrosis reacted with a decline in 
pulmonary artery pressure and pulmonary vascular esistance 
contrary to that predicted by in vitro studies (55). Similarly, in 
vitro studies in chronic obstructive lung disease suggest impair- 
ment of endothelium-dependent r laxation (56), yet the ma- 
jority of patients in a study by Adnot et al. (12) reacted with 
vasodilation to acetylcholine. Acetylcholine has been used for 
many years to test pulmonary vascular eactivity (57) and has 
been advocated as a pulmonary vasodilator in lieu of prosta- 
cyclin (58). Although the dose of acetylcholine used in the 
present study was similar to that prescribed by Wood (57), it is 
less than that recently advocated (12,58). Nevertheless, we 
reliably produced pulmonary vasoditation without systemic 
effects with 10 -6 tool/liter of acetylcholine in preoperative 
children with congenital heart disease (9). It remains possible 
that the response to acetylcholine in group II patients, who 
may have more severe endothelium dysfunction, would have 
been augmented with a higher dose. 
Our evaluation does not allow further isolation of the 
abnormal interaction between endothelial cells and the L- 
arginine nitric oxide pathway, but it does lend support o the 
accumulating evidence both in vitro and in vivo that the 
response to acetylcholine is attenuated in some patients with a 
long-term elevation of pulmonary artery pressure. 
Is nitric oxide the ideal agent? Nitric oxide is simple to 
deliver either by mask or ventilator. A trial of vasoreactivity 
over 15 rain remains free of side effects that might be encoun- 
tered during long-term administration, such as methemoglo- 
JACC Vol. 25, No. 7 ADATIA ET AL. 1663 
June 1995:1656-64 NITRIC OXIDE IN PULMONARY HYPERTENSION 
binemia or nitrogen dioxide toxicity. Indeed, no patient devel- 
oped significant methemoglobinemia, andneither was a level 
of nitrogen dioxide >1 ppm registered uring the administra- 
tion. Although the number of patients evaluated is small, it 
appears that nitric oxide gas fulfills many of the ideal charac- 
teristics, as recently suggested by Rubin (38), required of a 
drug to test the early responsiveness of the pulmonary circu- 
lation. It has better pulmonary than systemic dilating effects, a
short half-life, minimal adverse ffects and can be both easily 
and quickly administered. Whether it is able to predict reliably 
the effect of long-term administration f orally active agents 
awaits confirmation. However, nitric oxide should be used with 
caution in patients with an elevated left atrial pressure, and the 
administrator must be alert to the possibility of inducing 
pulmonary edema. 
Summary. This preliminary report suggests that in certain 
patients, inhaled nitric oxide is a potent pulmonary vasodilator 
with minimal systemic effects that may prove useful in the 
assessment of pulmonary hypertension. In patients with an 
elevated left ventricular end-diastolic pressure and pulmonary 
venous hypertension, itric oxide may aid in the selection of 
patients for heart or heart and lung transplantation. Its ease of 
administration, short half-life and absence of side effects make 
it a very suitable pulmonary vasodilator for use in the cardiac 
catheterization laboratory. It may have particular application 
in the assessment of patients with congenital heart disease 
when associated lesions preclude the safe use of intravenous 
vasodilators. 
We thank the respiratory therapists and catheterization laboratory staff for 
helping to make this study possible; Kim Gauvreau, PhD for statistical advice; 
and Cheryl King for preparation of the manuscript. 
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